Faculty of Biology, Medicine and Health

The University of Manchester

  (MRC DTP CASE) A platform for structural proteomics screening of membrane proteins

  ,  Friday, November 15, 2024  Competition Funded PhD Project (Students Worldwide)

About the Project

Solute carriers (SLCs) are the second largest class of membrane-embedded proteins with over 400 members organised into 66 families. SLCs are essential for catalysing the efficient transport across biological membranes of a wide range of compounds such as sugars, lipids, amino acids, nucleotides, and other metabolites. Whilst most SLCs are directly implicated in many diseases, they remain largely underexplored primarily due to the challenges they pose to study these complexes in their native environments. Another important class of membrane proteins is the G-Protein-Coupled Receptors (GPCRs). GPCRs are responsible for many pathological conditions, and constitute the targets of more than half of known drugs. Despite their importance, existing methods often fail to uncover information about the structural dynamics of GPCRs, precluding advances related to therapeutic interventions and drug discovery.   

Mass spectrometry (MS) has emerged as an extremely valuable tool for characterizing important membrane proteins and their complexes. Here, we aim to develop a novel MS-based platform that brings together cyclic hydrogen deuterium exchange (HDX)-MS with ion mobility (IM)-MS, native MS and EPR Spectroscopy. By leveraging the synergetic information of all methods to target SLCs and GPCRs, it will allow overcoming current limitations in chromatographic separations and capture their structural dynamics at unsurpassed level of resolution. A key aim of our approach is to obtain this information closer to their native environment. This will allow exploring currently unknown mechanisms that govern the function of SLCs such as allosteric effects and intrinsic dynamics in response to substrate and lipid binding.  

The development of our MS-based platform will unlock the SLC/GPCR family and allow novel drugs to be discovered against this important target class. In addition, we are exemplifying this potential using the potassium chloride cotransporter 2 (KCC2). KCC2 is a K-Cl transporter that is responsible for transporting Cl- (as a Cl- K+ pair) out of neurons. It works together with the Na++ Cl− co-transporter 1 (NKCC1) which imports Cl- into neurons, and the KCC2/NKCC1 ratio ultimately regulates chloride homeostasis. 

Reduced cell surface expression of WT KCC2 has been found to increase seizure susceptibility in mice models (kainate-induced epilepsy) (1). Several human mutations that either reduce the Cl- extrusion activity of KCC2 or the cell surface expression of KCC2 have been linked to patients with epilepsy (2). KCC2 therefore represents an attractive target for the therapeutic intervention of epilepsy, where compounds which positively modulate the activity of the carrier will restore chloride homeostasis. To date, no clinically developed drugs of solute carrier targets are positive allosteric modulators and therefore represent a challenge to the drug discovery industry. A significant hurdle is the need to perform compound screening with the transporter in its active, outward-open state – therefore allowing compounds which stabilise this conformation to be identified. HDX represents a potentially disruptive approach for these applications, since conditions can be optimised which increase the population of the therapeutically relevant conformation ahead of screening, currently not possible using traditional tools. 

https://politislab.uk/ 

Eligibility 

Applicants must have obtained or be about to obtain a minimum Upper Second class UK honours degree, or the equivalent qualifications gained outside the UK, in a relevant discipline.  

Before you Apply 

Applicants must make direct contact with preferred supervisors before applying. It is your responsibility to make arrangements to meet with potential supervisors, prior to submitting a formal online application.  

How to Apply 

To be considered for this project you MUST submit a formal online application form – on the application form you must select MRC DTP PhD Programme. If you select the incorrect programme your application cannot be considered. Full details on how to apply can be found on the MRC DTP website. 

Your application form must be accompanied by a number of supporting documents by the advertised deadlines. Without all the required documents submitted at the time of application, your application will not be processed and we cannot accept responsibility for late or missed deadlines. Incomplete applications will not be considered.  If you have any queries regarding making an application, please contact our admissions team.  

Equality, Diversity and Inclusion  

Equality, diversity and inclusion is fundamental to the success of The University of Manchester, and is at the heart of all of our activities. The full Equality, diversity and inclusion statement can be found on the website. 

Biological Sciences (4) Chemistry (6)

Funding Notes

This is a 4 year CASE studentship in partnership OMass Therapeutics. This covers tuition fees and an annual stipend. This does not include any costs associated with relocation.


References

1. Nam-Sik Woo, Jianming Lu, Roger England, Robert McClellan, Samuel Dufour, David B Mount, Ariel Y Deutch, David M Lovinger, Eric Delpire. Hyperexcitability and epilepsy associated with disruption of the mouse neuronal-specific K-Cl cotransporter gene. Hippocampus, 12 (2), 258-68, 2002.
2. Martin Puskarjov, Patricia Seja, Sarah E Heron, Tristiana C Williams, Faraz Ahmad, Xenia Iona, Karen L Oliver, Bronwyn E Grinton, Laszlo Vutskits, Ingrid E Scheffer , Steven Petrou, Peter Blaesse , Leanne M Dibbens , Samuel F Berkovic , and Kaila, A variant of KCC2 from patients with febrile seizures impairs neuronal Cl- extrusion and dendritic spine formation. EMBO Reports, 15(6), 723-9, 2014.

Open Days


Register your interest for this project



Where will I study?

Faculty of Biology, Medicine and Health

Tackle real world challenges, make a difference, and elevate your career with postgraduate research in the Faculty of Biology, Medicine and Health at Manchester. From biochemistry to neuroscience, cancer sciences to medicine, audiology to mental health and everything in between, we offer a wide range of postgraduate research projects, programmes and funding which will allow you to immerse yourself in an area of research you’re passionate about.

Why study at Faculty of Biology, Medicine and Health?

Ranked the best place to live in the UK (The Economist Global Liveability Index, 2022), Manchester boasts world-class culture, iconic sports, a thriving music and food scene, and much more. It's not just a place to research, it's a place to call home.

Experience PhD life as part of a diverse postgraduate research community of more than 1,000 postgraduate researchers at the 29th most international university in the world (Times Higher Education, 2023).

With 93% of research activity at the University rated as 'world-leading' or 'internationally excellent' (Research Excellence Framework, 2021), you'll get the chance to have an impact on global health and science challenges.

1000+

postgraduate students

221

PhDs

6

ranked in UK - QS (2025)

Manchester  United Kingdom

main campus

Upcoming Open Days & Webinars


About Faculty of Biology, Medicine and Health

At Manchester, postgraduate researchers are at the heart of our mission to tackle pressing global challenges in biological, medical and healthcare sciences - and you could be too.

By choosing Manchester for your postgraduate research, you’ll be joining a university with an exceptional research reputation, where 93% of research is world-leading or internationally excellent (REF, 2021) and where your work will have real-world impact.

You’ll research in world-class facilities alongside leading experts at the forefront of innovation, collaborating across disciplines to pioneer new treatments, advance scientific knowledge, and improve healthcare globally.

Supported by our dedicated Doctoral Academy and strong industry links, you'll experience PhD life in a vibrant, welcoming and diverse postgraduate research community.

And you’ll leave with the specialist knowledge, research experience and transferable skills that will shape your future in academia, research or industry.





Main campus

The University of Manchester

Manchester

North West

United Kingdom

PhD saved sucessfully

(International Partnership Studentship) Using white matter network alterations relating to stroke risk to predict cognitive and health outcomes

The project aims to investigate how age-related changes in brain white matter impact upon cognitive and health outcomes. Using advanced software and MRI data from the UK Biobank, the researchers will create effective cross-sectional and longitudinal models of how white matter abnormalities predict cognitive function. Read more
More details

(MB-PhD) Gene regulatory networks driving metastatic progression in oesophageal adenocarcinoma

Oesophageal adenocarcinoma (OAC) incidence is increasing and yet survival rates remain very poor. There are limited treatment options, especially for metastatic disease, which is especially problematic as patients usually present with late stage disease. Read more
More details

(MB-PhD) MYST Histone Acetyltransferases as Therapeutic Targets in Acute Myeloid Leukaemia

Cytotoxic chemotherapy has been the standard of care for treatment of acute myeloid leukaemia (AML) for the last 50 years. Unfortunately, more often than not, it fails to cure patients, and the 5 years survival rate for all-comers with AML is only around 20%. Read more
More details

(MB-PhD)Immunomodulation in multiple myeloma

Multiple myeloma is a devastating B-cell malignancy for which there is no cure. The development of immunomodulatory drugs (IMiDs) has proved transformative to multiple myeloma care, however, their remain unanswered questions related to the mechanism of action of this important drug class. Read more
More details

(MRC DTP CASE) Developing a cortical organoid model of genetic autism to understand early brain development

Neurodevelopmental conditions including autism and ADHD affect 4-8% of the paediatric population. These conditions present in the preschool period, are highly heritable and can severely affect quality of life, academic and occupational functioning. Read more
More details

(MRC DTP CASE) Drug Binding on human G-Protein Coupled Receptors under Tension-Altered Biomechanics in Diseases

Integral membrane proteins (MPs) constitute a significant part of the genome and are targets of ~30% of therapeutics. However, structural and functional understanding of these proteins often lags behind that of their soluble counterparts. Read more
More details

(MRC DTP) Circadian mechanisms in psoriasis: translating genomic and computational analysis to clinical care.

Despite numerous lines of evidence supporting a role for the circadian clock regulating multiple immunological axes, the dominant cell type driving rhythmic disease expression in psoriasis remains undetermined and there has been no progress on time-of-day regulation of psoriasis. Read more
More details

(MRC DTP) Combinatorial targeting of multiple disease mechanisms in drug-resistant epilepsy using microRNA inhibitors

Epilepsy is one of the most common chronic neurological diseases, affecting ~70 million people worldwide. Epilepsy is characterised by susceptibility to spontaneous seizures, and can also include challenges with cognition, sleep and mental health. Read more
More details